Project UpdateJun 25, 2026, 08:07 AM
MIRA Pharma Mira-55 Preclinical Data Shows Differentiated Profile
AI Summary
MIRA Pharmaceuticals announced new preclinical data for Mira-55, its cannabinoid analog in development for chronic inflammatory pain. The data revealed a differentiated mechanism of action and anxiolytic activity compared to THC, without its known liabilities like psychoactivity and central nervous system side effects. Mira-55 did not cause locomotor suppression or catalepsy and showed a distinct pharmacological mechanism for its effects. These positive findings support the continued advancement of Mira-55 towards an Investigational New Drug (IND) submission for chronic inflammatory pain.
Key Highlights
- Mira-55 demonstrated a differentiated mechanism of action and anxiolytic activity relative to THC.
- Preclinical data showed Mira-55 did not produce locomotor suppression or catalepsy associated with THC.
- Mira-55's modest body temperature reduction was not reversed by rimonabant, suggesting a distinct mechanism.
- Mira-55 exhibited anxiety-reducing activity, in contrast to anxiogenic activity observed with rimonabant.
- These findings support Mira-55's advancement toward an IND submission for chronic inflammatory pain.
- The data builds upon preclinical findings reported in March 2026.
Price Impact
More from MIRA